PMID- 24305063
OWN - NLM
STAT- MEDLINE
DCOM- 20140313
LR  - 20200930
IS  - 1522-1490 (Electronic)
IS  - 0363-6119 (Linking)
VI  - 306
IP  - 2
DP  - 2014 Jan 15
TI  - Effects of varying doses of testosterone on atherogenic markers in healthy 
      younger and older men.
PG  - R118-23
LID - 10.1152/ajpregu.00372.2013 [doi]
AB  - Whether exogenous testosterone is proatherogenic remains controversial. We 
      assessed the effects of graded doses of testosterone on serum markers of 
      oxidative stress, chemotaxis, adhesion, and inflammation in healthy younger and 
      older men. In a double-blind, randomized trial, 121 eugonadal men (n = 61, 18-35 
      years of age and n = 60, 60-75 years of age) were randomized to one of five 
      groups to receive weekly injections of 25, 50, 125, 300, or 600 mg of 
      testosterone enanthate for 20 wk, respectively, along with a long-acting 
      gonadotropin-releasing hormone (GnRH) agonist. Energy and protein intakes were 
      standardized and no resistance training was allowed. We measured plasma levels of 
      the atherogenic biomarkers monocyte chemotactic protein-1 (MCP-1), soluble 
      intracellular adhesion molecule-1 (sICAM-1), 8-isoprostane-PGF(2alpha) 
      (8-iso-PGF(2alpha)), and high-sensitivity C-reactive protein (hs-CRP) before and 
      after the intervention. Administration of increasing doses of testosterone led to 
      reduction in total 8-iso-PGF(2alpha) in the younger (p-trend(Younger) = 0.01), but 
      not older (p-trend(Older) = 0.79) men. No significant linear associations were 
      observed between testosterone dose and MCP-1, sICAM-1, or hs-CRP (all p-trend 
      >0.20). In apparently healthy men, over a wide dose range, testosterone did not 
      adversely affect atherogenic biomarkers. Long-term studies with larger sample 
      sizes are warranted to determine whether testosterone supplementation affects 
      atherosclerosis progression and cardiovascular risk.
FAU - Roberts, Christian K
AU  - Roberts CK
AD  - Exercise and Metabolic Disease Research Laboratory, Translational Sciences 
      Section, School of Nursing, University of California, Los Angeles, California; 
      and.
FAU - Chen, Brian H
AU  - Chen BH
FAU - Pruthi, Sandeep
AU  - Pruthi S
FAU - Lee, Martin L
AU  - Lee ML
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20131204
PL  - United States
TA  - Am J Physiol Regul Integr Comp Physiol
JT  - American journal of physiology. Regulatory, integrative and comparative 
      physiology
JID - 100901230
RN  - 0 (Androgens)
RN  - 3XMK78S47O (Testosterone)
RN  - 7Z6522T8N9 (testosterone enanthate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Aging
MH  - Androgens/administration & dosage/*pharmacology
MH  - Atherosclerosis/*chemically induced
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Testosterone/administration & dosage/*analogs & derivatives/pharmacology
MH  - Young Adult
OTO - NOTNLM
OT  - adhesion
OT  - androgen
OT  - atherosclerosis
OT  - chemotaxis
OT  - inflammation
OT  - oxidative stress
EDAT- 2013/12/07 06:00
MHDA- 2014/03/14 06:00
CRDT- 2013/12/06 06:00
PHST- 2013/12/06 06:00 [entrez]
PHST- 2013/12/07 06:00 [pubmed]
PHST- 2014/03/14 06:00 [medline]
AID - ajpregu.00372.2013 [pii]
AID - 10.1152/ajpregu.00372.2013 [doi]
PST - ppublish
SO  - Am J Physiol Regul Integr Comp Physiol. 2014 Jan 15;306(2):R118-23. doi: 
      10.1152/ajpregu.00372.2013. Epub 2013 Dec 4.